产品名称	KATO III人胃癌细胞
货号	ZQ0238
产品介绍	从一名55岁男性患者的胸腔积液中体外建立了人胃癌细胞系KATO-III。 KATO-III 细胞系是一种源自低分化腺癌转移部位的人类胃癌模型。这些细胞广泛用于胃癌研究，特别是用于研究驱动肿瘤进展、耐药性和转移的分子机制。KATO-III 细胞表现出非整倍体核型，其特征是多种染色体异常，这导致了它们的侵袭性癌症表型。它们明显缺乏 p53，这一特征通常与致瘤性增加和化疗反应改变有关，使其成为研究 p53 在胃癌中作用的宝贵工具。 KATO-III 细胞悬浮生长并呈现圆形形态。它们具有很高的增殖能力，使其适用于各种体外应用，包括药物筛选和细胞毒性测定。这些细胞还用于细胞信号通路的研究，因为它们的异常信号是胃癌发病机制的标志。研究人员经常利用 KATO-III 细胞探索新型治疗药物的疗效，尤其是针对 HER2、EGFR 和其他相关致癌途径的药物。该细胞系对于增进我们对胃癌生物学的了解以及开发旨在改善患者预后的靶向疗法至关重要。 注意事项： KATO III细胞为不均匀大小圆细胞，细胞形态为悬浮细胞和贴壁细胞共存生长。大部分圆细胞可以吹打，部分贴壁细胞需消化1min。
种属	人
性别/年龄	男/55岁
组织	胃；来源于转移部位:胸腔积液、锁骨上及腋窝淋巴结和道格拉斯氏陷凹
疾病	胃癌
细胞类型	肿瘤细胞
形态学	球形
生长方式	混合；贴壁和悬浮
倍增时间	大约32~41小时
培养基和添加剂	IMDM（中乔新舟  货号：ZQ-900）+20%胎牛血清（中乔新舟  货号：ZQ500-A）+1%双抗（中乔新舟 货号：CSP006）
推荐完全培养基货号	ZM0238
生物安全等级	BSL-1
STR位点信息	Amelogenin: X D3S1358: 15,16 TH01: 7,9 D21S11: 30,31 D18S51: 12 Penta_E: 13,18,19 D5S818: 10,11 D13S317: 8,12 D7S820: 8,12 D16S539: 10,12 CSF1PO: 7,11 Penta_D: 13,14 vWA: 14,16 D8S1179: 13,14 TPOX: 11 FGA: 23,24 D19S433: 13,16 D2S1338: 18,20
培养条件	95%空气，5%二氧化碳；37℃
抗原表达/受体表达	***
基因表达	***
保藏机构	ATCC; HTB-103 ECACC; 86093004
供应限制	仅供科研使用

货号	ZM0238
发货规格	活细胞：T25培养瓶*1瓶或者1ml 冻存管*1支（细胞量约为5 x 10^5 cells/vial）二选一
发货形式	活细胞：常温运输；冻存管：干冰运输
储存温度	活细胞：培养箱；冻存管：液氮罐
产地	中国
供应限制	仅供科研使用

CLPUB00581
Hojo H.
Establishment of cultured cell lines of human stomach cancer origin and their morphological characteristics.
Niigata Igakkai Zasshi 91:737-763(1977)

PubMed=209229
Sekiguchi M., Sakakibara K., Fujii G.
Establishment of cultured cell lines derived from a human gastric carcinoma.
Jpn. J. Exp. Med. 48:61-68(1978)

CLPUB00584

Motoyama T., Hojo H., Suzuki T., Oboshi S.
Evaluation of the regrowth assay method as an in vitro drug sensitivity test and its application to cultured human gastric cancer cell lines.
Acta Med. Biol. 27:49-63(1979)

PubMed=6862145; DOI=10.20772/cancersci1959.74.2_240
Naito S., Inoue S., Kinjo M., Tanaka K.
Thromboplastic and fibrinolytic activities of cultured human gastric cancer cell lines.
Gann 74:240-247(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3962675; DOI=10.1111/j.1440-1827.1986.tb01461.x
Motoyama T., Hojo H., Watanabe H.
Comparison of seven cell lines derived from human gastric carcinomas.
Acta Pathol. Jpn. 36:65-83(1986)

DOI=10.2198/sbk.34.289
Mizusawa H.
Operation of the JCRB cell bank and isoenzyme.
Seibutsu Butsuri Kagaku 34:289-292(1990)

PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x
Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M., Ohnishi Y., Xiao H.-Y., Nagai Y., Takagi H.
Aberrant elevation of tyrosine-specific phosphorylation in human gastric cancer cells.
Jpn. J. Cancer Res. 82:1428-1435(1991)

PubMed=1933850
Yamada Y., Yoshida T., Hayashi K., Sekiya T., Yokota J., Hirohashi S., Nakatani K., Nakano H., Sugimura T., Terada M.
p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases.
Cancer Res. 51:5800-5805(1991)

PubMed=1370612; DOI=10.1016/S0006-291X(05)80133-0
Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O., Wada K., Uchida T., Nishisaki H., Nagao M., Kasuga M.
Missense mutations and a deletion of the p53 gene in human gastric cancer.
Biochem. Biophys. Res. Commun. 182:215-223(1992)

DOI=10.1016/B978-0-12-333530-2.50014-9
Sekiguchi M., Suzuki T.
Gastric tumor cell lines.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York (1994)

PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)

PubMed=9247707; DOI=10.1080/15216549700202901
Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.
Expression of bone morphogenetic proteins of human neoplastic epithelial cells.
Biochem. Mol. Biol. Int. 42:497-505(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x
Yokozaki H.
Molecular characteristics of eight gastric cancer cell lines established in Japan.
Pathol. Int. 50:767-777(2000)

PubMed=11314020; DOI=10.1038/sj.onc.1204160
Kataoka H., Miura Y., Joh T., Seno K., Tada T., Tamaoki T., Nakabayashi H., Kawaguchi M., Asai K., Kato T., Itoh M.
Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1.
Oncogene 20:869-873(2001)

PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x
Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H., Okanoue T., Inazawa J.
Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization.
Cancer Sci. 96:100-110(2005)

PubMed=17505008; DOI=10.1158/1078-0432.CCR-06-2743
Takeda M., Arao T., Yokote H., Komatsu T., Yanagihara K., Sasaki H., Yamada Y., Tamura T., Fukuoka K., Kimura H., Saijo N., Nishio K.
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Clin. Cancer Res. 13:3051-3057(2007)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24587255; DOI=10.1371/journal.pone.0090155
Endo F., Nishizuka S.S., Kume K., Ishida K., Katagiri H., Ishida K., Sato K., Iwaya T., Koeda K., Wakabayashi G.
A compensatory role of NF-kappaB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines.
PLoS ONE 9:E90155-E90155(2014)

PubMed=24807215; DOI=10.1038/ncomms4830
Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M., Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M., Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C., Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G., Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S., Firestein R., Zhang Z.-M.
Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer.
Nat. Commun. 5:3830.1-3830.8(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29435981; DOI=10.1002/ijc.31304
Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C., Kragh M., Horak I.D., Chung H.C., Rha S.Y.
Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.
Int. J. Cancer 143:151-159(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32028591; DOI=10.3390/cancers12020334
Kim J.W., Min A., Im S.-A., Jang H., Kim Y.J., Kim H.-J., Lee K.-H., Kim T.-Y., Lee K.W., Oh D.-Y., Kim J.-H., Bang Y.-J.
TDP1 and TOP1 modulation in olaparib-resistant cancer determines the efficacy of subsequent chemotherapy.
Cancers (Basel) 12:334.1-334.17(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)